2024년에 2,481억 달러로 추정되는 원료의약품(API) 세계 시장은 2024-2030년간 CAGR 6.3%로 성장하여 2030년에는 3,585억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 혁신적 부문은 CAGR 6.0%를 나타내고, 분석 기간 종료시에는 2,408억 달러에 이를 것으로 예측됩니다. 제네릭 의약품 부문의 성장률은 분석 기간중 CAGR 6.9%로 추정됩니다.
미국 시장은 추정 773억 달러, 중국은 CAGR 6.6%로 성장 예측
미국의 원료의약품(API) 시장은 2024년에 773억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 519억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.6%로 예상됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 5.6%와 6.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.6%를 보일 전망입니다.
세계의 원료의약품(API) 시장 - 주요 동향과 촉진요인 정리
원료의약품(API)은 의도한 치료 효과를 내는 의약품의 중요한 구성 요소입니다. API는 천연 유래와 실험실 합성으로 나뉘며, 안전성과 유효성을 보장하기 위해 엄격한 규제 기준을 충족시켜야 하는 등 다양한 화학적, 생물학적 공정을 통해 제조됩니다. 원료의약품의 제조에는 화학 합성, 발효, 재조합 DNA 기술, 천연물로부터의 분리 등 복잡한 공정이 포함되며, 이는 의약품 제조의 중요한 측면이 되고 있습니다.
원료의약품은 정제, 캡슐제, 주사제, 외용제 등 다양한 제형에 사용됩니다. 감염이나 통증과 같은 일반적인 질환부터 당뇨병, 암, 심혈관 질환과 같은 만성질환까지 다양한 질환의 치료에 필수적인 요소입니다. 원료의약품의 품질과 순도는 최종 의약품의 안전성과 유효성에 직접적인 영향을 미치기 때문에 엄격한 품질 관리와 적정 제조 기준(GMP) 준수가 필요합니다. 제약업계는 신약 개발 및 기존 치료법 개선에 있어 원료의약품에 크게 의존하고 있으며, 원료의약품은 현대 의학의 핵심입니다.
원료의약품 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 만성 질환의 유병률 증가와 효과적이고 혁신적인 의약품에 대한 수요 증가가 주요 촉진요인이며, API 제조 공정의 기술 발전은 생산 효율을 높이고 비용을 절감하며 시장 확대를 뒷받침하고 있습니다. 특히 신흥 시장에서 원료의약품 제조를 전문 제조업체에 위탁하는 추세가 강화되고 있는 것도 성장에 기여하고 있습니다. 또한, 의약품의 품질과 안전에 대한 엄격한 규제 요건으로 인해 제약사들이 고품질 원료의약품 생산에 대한 투자를 늘리고 있습니다. 바이오의약품의 부상과 개인 맞춤형 의료의 발전은 첨단 원료의약품에 대한 수요를 더욱 증가시키고 있으며, 이는 제약 산업의 역동적이고 진화하는 특성을 더욱 부각시키고 있습니다.
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global Active Pharmaceutical Ingredients (API) Market to Reach US$358.5 Billion by 2030
The global market for Active Pharmaceutical Ingredients (API) estimated at US$248.1 Billion in the year 2024, is expected to reach US$358.5 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the end of the analysis period. Growth in the Generic segment is estimated at 6.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$77.3 Billion While China is Forecast to Grow at 6.6% CAGR
The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$77.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$51.9 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.
Global Active Pharmaceutical Ingredients (API) Market - Key Trends & Drivers Summarized
Active Pharmaceutical Ingredients (APIs) are the critical components in pharmaceutical products that produce the intended therapeutic effects. These innovative and generic ingredients are responsible for the drug's efficacy and are manufactured through various chemical and biological processes. APIs can be derived from natural sources or synthesized in laboratories, and they must meet stringent regulatory standards to ensure safety and effectiveness. The production of APIs involves complex processes, including chemical synthesis, fermentation, recombinant DNA technology, and isolation from natural sources, making it a crucial aspect of pharmaceutical manufacturing.
APIs are used in a wide range of pharmaceutical formulations, including tablets, capsules, injectables, and topical preparations. They are essential in the treatment of numerous conditions, ranging from common ailments like infections and pain to chronic diseases such as diabetes, cancer, and cardiovascular disorders, among others. The quality and purity of APIs directly impact the safety and efficacy of the final pharmaceutical product, necessitating rigorous quality control and adherence to Good Manufacturing Practices (GMP). The pharmaceutical industry relies heavily on APIs to develop new drugs and improve existing treatments, making them a cornerstone of modern medicine.
The growth in the active pharmaceutical ingredients market is driven by several factors. Increasing prevalence of chronic diseases and the rising demand for effective and innovative medications are major drivers. Technological advancements in API manufacturing processes have enhanced production efficiency and reduced costs, supporting market expansion. The growing trend towards outsourcing API production to specialized manufacturers, particularly in emerging markets, has also contributed to growth. Additionally, stringent regulatory requirements for drug quality and safety are pushing pharmaceutical companies to invest in high-quality API production. The rise of biopharmaceuticals and the development of personalized medicine are further propelling the demand for advanced APIs, underscoring the dynamic and evolving nature of the pharmaceutical industry.
SCOPE OF STUDY:
The report analyzes the Active Pharmaceutical Ingredients (API) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Innovative, Generic); Synthesis (Synthetic, Biotech); Application (Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic, Other Applications)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.
Select Competitors (Total 266 Featured) -
Alkem Laboratories Limited
Albemarle Corporation
Ajinomoto Co., Inc.
Apotex, Inc.
AbbVie, Inc.
Almac Group
Amneal Pharmaceuticals, Inc.
Aspen Pharmacare Holdings Ltd.
Alembic Pharmaceuticals Limited
Amsal Chem Pvt., Ltd.
Arch Pharmalabs Ltd.
AmbioPharm, Inc.
ACIC Pharmaceuticals, Inc.
American Pacific Corporation
ACS Dobfar S.p.A.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Tariff Impact on Global Supply Chain Patterns
Competition
Active Pharmaceutical Ingredients (API) - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
Active Pharmaceutical Ingredients: A Prelude
Global Active Pharmaceutical Ingredients Market Set to Witness Rapid Growth
Regional Landscape
North America Dominates the Global API Market
US CDMOs to Gain from Mounting Concerns Over Excess Reliance On Chinese APIs
China Continues to Remain a Major Hub
India Strives to Increase API Production to Attain Self Reliance in Pharmaceutical Production
Global PE Firms to Invest Heavily in Indian Intermediate Pharma Companies
Leading Players
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Sustained Increase in Drug R&D Spending to Drive API Market
Increased API Sourcing Creates the need for More Scrutiny of Suppliers for Best Quality Products
Preference for Specialized CDMO Contractors on the Rise
Strong Rise in Pharmaceutical Sales to Drive Demand
Global Prescription Drug Sales (In US$ Billion) for the Years 2000-2025
The AIC Approach for Faster Assessment of Viable Drug Candidates
Drug Makers Embrace Digital Technology
Digital Transformation Spending in US$ Billion in Pharma Sector: 2020 and 2027
Demand for HPAPIs on the Rise
AI Finds Growing Application in Drug Discovery and Development
Microdosing Beneficial for the Formulation of High Potency Ingredients
Growing Penetration of Generic Drugs Augments Market Prospects
Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
Increasing Interest in Biopharmaceuticals Supports Market Demand
Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
Rising Number of Biologics Approvals Augurs Well
Growing Biosimilars Market Create Opportunities for APIs
Global Biosimilars Market in US$ Billion: 2020 & 2025
Growing Attention Towards Personalized Medicine Spurs Demand for Complex API
Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
Increasing Sales of OTC Drugs Presents an Opportunity for APIs
Global OTC Drugs Market Breakdown by Product (in %): 2024E
Growing Prevalence of Infectious Diseases to Spur Growth
Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Rising Incidence of Cancer & Need to Reduce Cancer-Related Mortality Spell Increased Demand
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Increasing Prevalence of Chronic Disorders Fuels Market Growth
World Diabetes and Population Statistics (2019, 2030 & 2045)
Rising Incidence of Cardiovascular Diseases Revs Up Opportunities
Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Upsurge in ANDA Approvals Bodes Well
Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Novel Technology for Continuous Manufacturing of APIs
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Active Pharmaceutical Ingredients (API) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for CNS & Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Orthopedic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
JAPAN
TABLE 56: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
CHINA
TABLE 65: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
EUROPE
Market Facts & Figures
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
FRANCE
TABLE 86: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
GERMANY
TABLE 95: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
TABLE 113: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2015, 2025 & 2030
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2015, 2025 & 2030
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2015, 2025 & 2030
